Membrane lipidomics for the discovery of new antiparasitic drug targets

Trends in Parasitology

Volumn 27, Issue 11, 2011, Pages 496-504

  Maréchal, Eric ^a   Riou, Mickaël ^b   Kerboeuf, Dominique ^c   Beugnet, Frédéric ^d   Chaminade, Pierre ^e   Loiseau, Philippe M ^f  

^a CNRS   (France)

^b CEMAGREF   (France)

^c UR1282   (France)

^d Faculté de Pharmacie ^*  (France)

^e University Paris Saclay   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIPARASITIC AGENT; CARDIOLIPIN; EDELFOSINE; FATTY ACID SYNTHASE; LIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; SITAMAQUINE; THIOLACTOMYCIN; TRICLOSAN;

AMOEBOZOA; APICOMPLEXA; APICOPLAST; CELL DIFFERENTIATION; CELL DIVISION; DRUG DESIGN; DRUG TARGETING; ELECTROSPRAY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HYDROPHOBICITY; LEISHMANIA; LIPID ANALYSIS; LIPID COMPOSITION; LIPID METABOLISM; LIPIDOMICS; LIPOGENESIS; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PARASITE MEMBRANE LIPIDOMICS; PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY;

PROTISTA; VERTEBRATA;

EID: 80054789441     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2011.07.002     Document Type: Review

References (75)

1. Maurya R., et al. Evaluation of blood agar microtiter plates for culturing Leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J. Clin. Microbiol. 2010, 48:1932-1934.
2. Dietz K., et al. Mathematical model of the first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals. Am. J. Trop. Med. Hyg. 2006, 75:46-55.
3. Geraghty E.M., et al. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin. Infect. Dis. 2007, 44:e82-e84.
4. Loverde P.T., Chen L. Schistosome female reproductive development. Parasitol. Today 1991, 7:303-308.
5. Bethony J., et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006, 367:1521-1532.
6. Saidani N., et al. Potential and limits of in silico target discovery - case study of the search for new antimalarial chemotherapeutic targets. Infect. Genet. Evol. 2009, 9:359-367.
7. Ben Mamoun C., et al. Targeting the lipid metabolic pathways for the treatment of malaria. Drug Dev. Res. 2010, 71:44-55.
8. Shevchenko A., Simons K. Lipidomics: coming to grips with lipid diversity. Nat. Rev. Mol. Cell Biol. 2010, 11:593-598.
9. Dennis E.A. Lipidomics joins the omics evolution. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2089-2090.
10. Kita Y., et al. Lipidomics approaches for a comprehensive analysis of fatty acids and metabolites by LC/ESI-MS. Prostaglandins Other Lipid Mediat. 2006, 79:150-151.
11. Wenk M.R. The emerging field of lipidomics. Nat. Rev. Drug Discov. 2005, 4:594-610.
12. McKee D.L. Lipidomics. Scientist 2003, 17:20.
13. Lagarde M., et al. Lipidomics is emerging. Biochim. Biophys. Acta 2003, 1634:61.
14. Feng L., et al. Lipidomics: probing lipid-protein interactions using immobilized lipids. FASEB J. 2003, 17:A993-A994.
15. Hsiao L.L., et al. Modification of host cell membrane lipid composition by the intra-erythrocytic human malaria parasite Plasmodium falciparum. Biochem. J. 1991, 274:121-132.
16. Welti R., et al. Lipidomic analysis of Toxoplasma gondii reveals unusual polar lipids. Biochemistry 2007, 46:13882-13890.
17. Botte C., et al. Subcellular localization and dynamics of a digalactolipid-like epitope in Toxoplasma gondii. J. Lipid Res. 2008, 49:746-762.
18. Besteiro S., et al. Export of a Toxoplasma gondii rhoptry neck protein complex at the host cell membrane to form the moving junction during invasion. PLoS Pathog. 2009, 5:e1000309.
19. Azzouz N., et al. Toxoplasma gondii grown in human cells uses GalNAc-containing glycosylphosphatidylinositol precursors to anchor surface antigens while the immunogenic Glc-GalNAc-containing precursors remain free at the parasite cell surface. Int. J. Biochem. Cell Biol. 2006, 38:1914-1925.
20. Azzouz N., et al. Removal of phospholipid contaminants through precipitation of glycosylphosphatidylinositols. Anal. Biochem. 2005, 343:152-158.
21. Riou M., et al. Immunolocalisation of an ABC transporter, P-glycoprotein, in the eggshells and cuticles of free-living and parasitic stages of Haemonchus contortus. Parasitol. Res. 2005, 96:142-148.
22. Riou M., et al. Modulation of the multidrug resistance (MDR) system in the nematode Haemonchus contortus by changing cholesterol content: effects on resistance to anthelmintics. J. Antimicrob. Chemother. 2003, 52:180-187.
23. Navas-Iglesias N., et al. From lipids analysis towards lipidomics, a new challenge for the analytical chemistry of the 21st century. Part II: analytical lipidomics. Trends Anal. Chem. 2009, 28:393-403.
24. Schwudke D., et al. Top-down lipidomic screens by multivariate analysis of high-resolution survey mass spectra. Anal. Chem. 2007, 79:4083-4093.
25. Zheng L., et al. Profiling of lipids in Leishmania donovani using hydrophilic interaction chromatography in combination with Fourier transform mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24:2074-2082.
26. Griffiths W.J., Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem. Soc. Rev. 2009, 38:1882-1896.
27. Willmann J., et al. Hyphenated tools for phospholipidomics. J. Biomol. Tech. 2008, 19:211-216.
28. Haynes C.A., et al. Sphingolipidomics: methods for the comprehensive analysis of sphingolipids. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2009, 877:2696-2708.
29. Roberts L.D., et al. A matter of fat: an introduction to lipidomic profiling methods. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2008, 871:174-181.
30. Lehtonen M., et al. Determination of endocannabinoids in nematodes and human brain tissue by liquid chromatography electrospray ionization tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2011, 879:677-694.
31. Schiller J., et al. MALDI-TOF MS in lipidomics. Front. Biosci. 2007, 12:2568-2579.
32. Han X., Gross R.W. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 2005, 24:367-412.
33. Cai S.S., et al. Comparison of atmospheric pressure photoionization and atmospheric pressure chemical ionization for normal-phase LC/MS chiral analysis of pharmaceuticals. Anal. Chem. 2007, 79:2491-2498.
34. Sandra K., et al. Comprehensive blood plasma lipidomics by liquid chromatography/quadrupole time-of-flight mass spectrometry. J. Chromatogr. A 2010, 1217:4087-4099.
35. Riou M., et al. Relationships between sterol/phospholipid composition and xenobiotic transport in nematodes. Parasitol. Res. 2007, 100:1125-1134.
36. Fuchs B., et al. Lipid analysis by thin-layer chromatography - a review of the current state. J. Chromatogr. A 2010, 1218:2754-2774.
37. Azzouz N., et al. Metabolic labeling and structural analysis of glycosylphosphatidylinositols from parasitic protozoa. Methods Mol. Biol. 2008, 446:183-198.
38. Marechal E., et al. Synthesis of chloroplast galactolipids in apicomplexan parasites. Eukaryot. Cell 2002, 1:653-656.
39. Bisanz C., et al. Toxoplasma gondii acyl-lipid metabolism: de novo synthesis from apicoplast-generated fatty acids versus scavenging of host cell precursors. Biochem. J. 2006, 394:197-205.
40. Surolia N., Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7:167-173.
41. Charron A.J., Sibley L.D. Host cells: mobilizable lipid resources for the intracellular parasite Toxoplasma gondii. J. Cell Sci. 2002, 115:3049-3059.
42. Mazumdar J., et al. Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:13192-13197.
43. Lemmon M.A. Phosphoinositide recognition domains. Traffic 2003, 4:201-213.
44. Backer J.M. New methods for capturing the mystery lipid, PtdIns5P. Biochem. J. 2010, 428:e1-e2.
45. Tawk L., et al. Phosphatidylinositol 3-monophosphate is involved in toxoplasma apicoplast biogenesis. PLoS Pathog. 2010, 7:e1001286.
46. Riou M., et al. Drug resistance is affected by colocalization of P-glycoproteins in raft-like structures unexpected in eggshells of the nematode Haemonchus contortus. Biochem. Cell Biol. 2010, 88:459-467.
47. Ferguson M.A., et al. Glycosyl-phosphatidylinositol molecules of the parasite and the host. Parasitology 1994, 108(Suppl.):S45-S54.
48. Debierre-Grockiego F., et al. Binding of Toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages. J. Biol. Chem. 2010, 285:32744-32750.
49. Sonda S., Hehl A.B. Lipid biology of Apicomplexa: perspectives for new drug targets, particularly for Toxoplasma gondii. Trends Parasitol. 2006, 22:41-47.
50. Landoni M., et al. Plasmodium falciparum biosynthesizes sulfoglycosphingolipids. Mol. Biochem. Parasitol. 2007, 154:22-29.
51. Boutlis C.S., et al. Antibodies to Plasmodium falciparum glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults. Infect. Immun. 2002, 70:5052-5057.
52. Birkholtz L.M., et al. Integration and mining of malaria molecular, functional and pharmacological data: how far are we from a chemogenomic knowledge space?. Malar. J. 2006, 5:110.
53. Kanehisa M., et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38:D355-D360.
54. Caspi R., et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. Nucleic Acids Res. 2010, 38:D473-D479.
55. Ginsburg H., Tilley L. Plasmodium falciparum metabolic pathways (MPMP) project upgraded with a database of subcellular locations of gene products. Trends Parasitol. 2011, 27:285-286.
56. Waller R.F., et al. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob. Agents Chemother. 2003, 47:297-301.
57. Prigge S.T., et al. The initiating steps of a type II fatty acid synthase in Plasmodium falciparum are catalyzed by pfACP, pfMCAT, and pfKASIII. Biochemistry 2003, 42:1160-1169.
58. McLeod R., et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int. J. Parasitol. 2001, 31:109-113.
59. Yu M., et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 2008, 4:567-578.
60. Baschong W., et al. Triclosan is minimally effective in rodent malaria models. Nat. Med. 2011, 17:33-34. 34-35 author reply.
61. Surolia A., Surolia N. Triclosan is minimally effective in rodent malaria models - reply. Nat. Med. 2011, 17:34-35.
62. Besteiro S., et al. Exploring metabolomic approaches to analyse phospholipid biosynthetic pathways in Plasmodium. Parasitology 2010, 137:1343-1356.
63. Dechamps S., et al. Rodent and nonrodent malaria parasites differ in their phospholipid metabolic pathways. J. Lipid Res. 2010, 51:81-96.
64. Caldarelli S.A., et al. Exploration of potential prodrug approach of the bis-thiazolium salts T3 and T4 for orally delivered antimalarials. Bioorg. Med. Chem. Lett. 2010, 20:3953-3956.
65. Ibrahim H.M., et al. Symmetrical choline-derived dications display strong anti-kinetoplastid activity. J. Antimicrob. Chemother. 2010, 66:111-125.
66. Cohen B.E. Concentration- and time-dependence of amphotericin-B induced permeability changes across ergosterol-containing liposomes. Biochim. Biophys. Acta 1986, 857:117-122.
67. Rakotomanga M., et al. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 2005, 49:2677-2686.
68. Baginski M., et al. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim. Biophys. Acta 2002, 1567:63-78.
69. Resat H., Baginski M. Ion passage pathways and thermodynamics of the amphotericin B membrane channel. Eur. Biophys. J. 2002, 31:294-305.
70. Saint-Pierre-Chazalet M., et al. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. J. Antimicrob. Chemother. 2009, 64:993-1001.
71. Hac-Wydro K., et al. Langmuir monolayer study toward combined antileishmanian therapy involving amphotericin B and edelfosine. J. Phys. Chem. B 2009, 113:14239-14246.
72. Lopez-Martin C., et al. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob. Agents Chemother. 2008, 52:4030-4036.
73. Duenas-Romero A.M., et al. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochim. Biophys. Acta 2007, 1768:246-252.
74. Kerboeuf D., et al. Membrane drug transport in helminths. Anti-Infective Agents Med. Chem. 2010, 9:113-129.
75. Barratt G., et al. Cellular transport and lipid interactions of miltefosine. Curr. Drug Metab. 2009, 10:247-255.